FDA to review approval application for seladelpar as PBC treatment
The U.S. Food and Drug Administration (FDA) will review CymaBay Therapeutics’ application for seladelpar, an oral investigational treatment for adults with…
Steve Bryson, PhD, Science Writer — 
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
Articles by Steve Bryson
Recent Posts
- Biliary atresia patient spotlighted in 2025 ALF Liver Life Walk
- How I advocated for my brother before and after his PSC diagnosis
- Researchers uncover how hepatitis B virus can persist in liver cells
- CM-101 (nebokitug) set for primary sclerosing cholangitis Phase 3 trial
- Researchers develop tool to predict drug-induced cholestasis